Form 4: EyePoint Pharmaceuticals CEO Transfers Shares to Family Trust

Jay S. Duker, CEO of EyePoint Pharmaceuticals, sold 20,000 shares to a family trust at $6.155 per share and disclaims beneficial ownership of shares held by the trust.

Summary

• On March 19, 2025, Jay S. Duker, the President and CEO of EyePoint Pharmaceuticals, sold 20,000 shares of common stock at a price of $6.155 per share.
• The shares were sold to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note of $123,100.
• Following the transaction, Duker directly owns 57,651 shares of common stock.
• Duker also indirectly owns 42,500 shares through the Family Trust, for the benefit of his children, but disclaims beneficial ownership of these shares.
• Duker's spouse is a trustee of the Family Trust.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard Form 4 filing indicating a transfer of shares to a family trust, with no inherent positive or negative implications for the company's performance.

Industry Context

This is a routine disclosure of insider transactions. It's common for executives to manage their holdings for personal financial planning, including estate planning through trusts.

Related Party Transactions

• The sale of 20,000 shares to the Duker Family 2024 Irrevocable Trust is a related party transaction.

Stakeholder Impact

• The transaction itself is unlikely to have a significant impact on stakeholders, as it is a transfer of shares for estate planning purposes.
• The CEO's continued leadership and ownership stake remain.

Key Dates

Keywords

EyePoint Pharmaceuticals, Jay S. Duker, Form 4, Beneficial Ownership, Family Trust, Share Transaction, EYPT